BLOG

Benzinga

eFFECTOR Therapeutics Collaborates With Stanford Medicine Mid-Stage Breast Cancer Study

eFFECTOR Therapeutics Inc will collaborate with Stanford Medicine on an investigator-initiated randomized Phase 2 study evaluating zotatifin in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a preoperative setting.